Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Activating point mutations in Anaplastic Lymphoma Kinase (ALK) have positioned ALK as the only mutated oncogene tractable for targeted therapy in neuroblastoma. Cells with these mutations respond to lorlatinib in pre-clinical studies, providing the rationale for a first-in-child Phase 1 trial (NCT03107988) in patients with ALK-driven neuroblastoma. To track evolutionary dynamics and heterogeneity of tumors, and to detect early emergence of lorlatinib resistance, we collected serial circulating tumor DNA samples from patients enrolled on this trial. Here we report the discovery of off-target resistance mutations in 11 patients (27%), predominantly in the RAS-MAPK pathway. We also identify newly acquired secondary compound ALK mutations in 6 (15%) patients, all acquired at disease progression. Functional cellular and biochemical assays and computational studies elucidate lorlatinib resistance mechanisms. Our results establish the clinical utility of serial circulating tumor DNA sampling to track response and progression and to discover acquired resistance mechanisms that can be leveraged to develop therapeutic strategies to overcome lorlatinib resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Fig. 6 Structural modeling of lorlatinib resistance due to compound mutations. The color designations for ALK variants in this figure are as follows: F1174L (red) F1174L/G1202R (dark red), F1174L/L1196M (medium red), R1275Q (blue), R1275/G1202R (dark blue), R1275Q/L1196M (medium blue), L1196M (purple), and G1202R (gold). a Structure of wild-type ALK-TKD with bound lorlatinib (PDB ID: 4CLI15), highlighting the positions of key structural elements, a bound lorlatinib molecule (green), F1174 (red), R1275 (blue), L1196 (purple) and G1202 (gold). b Distribution of lorlatinib-docking scores for modeled ALK-TKD variants, with lower (more negative) docking scores corresponding to increased binding energy. The docking scores were generated with n of 10 independently run induced fit docking experiments. For each variant, the filled symbol in the boxplot represents the mean, the horizontal line within the box represents the median, and upper and lower bounds of the box represent the 75th and 25th percentiles (to give interquartile range). The upper and lower whiskers represent the maximum and minimum values of the data that are within 1.5 times the interquartile range. c Best-fit docked lorlatinib (medium red) pose in the F1174L/L1196M ALK-TKD variant (docking score −10.213 kcal/mol), with lorlatinib shown in red and conserved interactions (blue dashed lines) with E1197 and M1199 of the hinge region marked, as well as position 1196 (replaced with M). d Best-docked lorlatinib pose for F1174L/G1202R (docking score −12.033 kcal/mol) showing conserved interactions (blue dashed lines) with E1197 and M1199 of the hinge region and the arginine introduced at position 1202. e Positions of R1202 and L1122 in the F1174L/G1202R ALK-TKD model in both the gate-open (left) and gate-closed (right) conformations, showing that ATP (green) placed as in PDB ID 3BU555 (bottom) can bind either conformation, whereas lorlatinib placed as in PDB ID: 4CLI15 (top) can only bind the gate-open conformation. f Plot of the percentage of time in the 300 ns MD simulations that each ALK-TKD variant noted spends in the gate-open conformation. Note that the F1174L/G1202R variant spends 10% of the time with the gate ʻopenʼ, and ~90% with the gate closed. g Lorlatinib inhibition curves generated in silico for R1275Q-based variants as described in Methods and Supplementary Note 2, with [ALK-TKD] set at 5 nM, and [ATP] at 1 mM, using only the gate-open kinetic model. h Lorlatinib inhibition curves generated in silico for F1174L-based variants as described in h. Curves for ALK-TKD with the F1174L (red circles, solid curve) or F1174L/L1196M (medium red diamonds, dashed curve) mutation were unaffected by whether or not the gate was allowed to close (see Supplementary Data Fig. 8e). Only with the gate closed ~90% of the time as predicted in f see Supplementary Data Fig. 8a, b) did the F1174L/G1202R variant (dark red squares, dotted curve) show the increased IC50 value plotted here. Source data are provided as a Source Data file.](https://figures.cochat.ai/paper-figures/83dc89b3231e417aa22c8605fdc164e8/circulating-tumor-dna-reveals-mechanisms-of-lorlatinib-resistance-in-patients-figure-6.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Prior work has demonstrated the utility of liquid biopsies for detection of ALK mutations in patients with NBL to inform targeted therapies.19,26”
From Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study (2026) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparison of simple potential functions for simulating liquid water
Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., & Klein, M. L. (1983) · The Journal of Chemical Physics · doi:10.1063/1.445869 · Cited by 41,298
Molecular dynamics with coupling to an external bath
Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W. F., DiNola, A., & Haak, J. R. (1984) · The Journal of Chemical Physics · doi:10.1063/1.448118 · Cited by 30,700
Polymorphic transitions in single crystals: A new molecular dynamics method
Parrinello, M., & Rahman, A. (1981) · Journal of Applied Physics · doi:10.1063/1.328693 · Cited by 19,790
All-Atom Empirical Potential for Molecular Modeling and Dynamics Studies of Proteins
MacKerell, A. D., Bashford, D., Bellott, M., Dunbrack, R. L., Evanseck, J. D., Field, M. J., Fischer, S., Gao, J., Guo, H., Ha, S., et al. (1998) · The Journal of Physical Chemistry B · doi:10.1021/jp973084f · Cited by 14,311
Comparative Protein Modelling by Satisfaction of Spatial Restraints
Šali, A., & Blundell, T. L. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1626 · Cited by 12,977
Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306430 · Cited by 10,057
GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit
Pronk, S., Páll, S., Schulz, R., Larsson, P., Bjelkmar, P., Apostolov, R., Shirts, M. R., Smith, J. C., Kasson, P. M., van der Spoel, D., et al. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt055 · Cited by 7,473
Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., & Mainz, D. T. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051256o · Cited by 6,851
Halgren, T. A., Murphy, R. B., Friesner, R. A., Beard, H. S., Frye, L. L., Pollard, W. T., & Banks, J. L. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030644s · Cited by 5,177
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190 · cited 1×
“Six patients (2, 13, 14, 26, 31, 32) acquired new RAS-MAPK/PI3K pathway alterations during treatment, nearly always preceding clinical/radiographic diseaseprogression.”
Background
Cited by
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells
Bergaggio, E., Tai, W., Aroldi, A., Mecca, C., Landoni, E., Nüesch, M., Mota, I. A., Metović, J., Molinaro, L., Ma, L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.11.004 · Cited by 66
ALK in cancer: from function to therapeutic targeting
Voena, C., Ambrogio, C., Iannelli, F., & Chiarle, R. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00797-9 · Cited by 55
“However, neuroblastoma that developed resistance to lorlatinib shows enrichment of mutations in the MAPK and PI3K pathways, including oncogenic alterations of MET, BRAF, EGFR, FGFR1, PTPN11, PIK3CA and RAS GTPases 185,205 .”
Grossmann, L. D., Chen, C.-H., Uzun, Y., Thadi, A., Wolpaw, A. J., Louault, K., Goldstein, Y., Surrey, L. F., Martínez, D., Calafatti, M., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0046 · Cited by 45
“39–41 As our data do not support the acquisition of new genetic aberrations during induction therapy as a major driver of cellular persistence, we sought to determine the association between persister subtypes and genetic events present at diagnosis.”
Self-citationKiełbowski, K., Żychowska, J., & Becht, R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1285374 · Cited by 28
Berko, E. R., Naranjo, A. H., Daniels, A. A., McNulty, S. N., Krytska, K., Druley, T. E., Zelley, K., Koneru, B., Chen, L., Polkosnik, G., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02407 · Cited by 22
Self-citation
Metadata
- Authors
- Berko, E. R., Witek, G. M., Matkar, S., Petrova, Z. O., Wu, M. A., Smith, C. M., Daniels, A., Kalna, J., Kennedy, A., Gostuski, I., Casey, C., Krytska, K., Gerelus, M., Pavlick, D., Ghazarian, S., Park, J. R., Marachelian, A., Maris, J. M., Goldsmith, K. C., Radhakrishnan, R., Lemmon, M. A., & Mossé, Y. P.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Yale University (US)
- University of Pennsylvania (US)
- Foundation Medicine (United States) (US)
- University of Southern California (US)
- St. Jude Children's Research Hospital (US)
- Seattle Children's Hospital (US)
- Corresponding author
- Lemmon, Mark A.
- Mossé, Yaël P.
- ORCID
- Venue
- Nature Communications
- Published
- 2023-05-05
- Volume
- 14
- Issue
- 1
- Pages
- 2601-2601
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC10163008
- OpenAlex
- W4372294503
- Cited by
- 53
- References
- 71
- Citations by year
- 2026: 17 · 2025: 19 · 2024: 13 · 2023: 4
- FWCI
- 8.97
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA217959, CA140198)
- Solving Kids' Cancer
- Cookies for Kids Cancer The EVAN Foundation
- U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM122485)
- Topics
- Health Sciences › Medicine › Oncology › Neuroblastoma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- lorlatinib resistance, circulating tumor DNA, anaplastic lymphoma kinase, acquired resistance, relapsed/refractory neuroblastoma, targeted therapy, tumor heterogeneity
- MeSH terms
- Circulating Tumor DNA, Anaplastic Lymphoma Kinase, Aminopyridines, Carcinoma, Non-Small-Cell Lung, Humans, Lactams, Lung Neoplasms, Mutation, Neuroblastoma, Pyrazoles, Drug Resistance, Neoplasm, Lactams, Macrocyclic, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma. https://app.cochat.ai/papers/10.1038/s41467-023-38195-0
- The paper
- Berko, E. R., Witek, G. M., Matkar, S., Petrova, Z. O., Wu, M. A., Smith, C. M., Daniels, A., Kalna, J., Kennedy, A., Gostuski, I., Casey, C., Krytska, K., Gerelus, M., Pavlick, D., Ghazarian, S., Park, J. R., Marachelian, A., Maris, J. M., Goldsmith, K. C., . . . Mossé, Y. P. (2023). Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma. Nature Communications. https://doi.org/10.1038/s41467-023-38195-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.